Neoadjuvant Anti-PD-1 Antibody SHR-1210 and Radiation in Resectable Esophageal Squamous Cell Carcinoma

Clinical trial NCT03200691 · UNKNOWN

Trial details

NCT number: NCT03200691
Sponsor: Hangzhou Cancer Hospital
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Esophageal Neoplasms Esophageal Diseases

Start date: 2017-08-10
Primary completion: 2018-06-30
Enrollment: 21

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.